Skip to contentF
Filana Therapeutics, Inc.
F
FLNAFilana Therapeutics, Inc. Q1 2015 · 10-Q
Revenue—
Net Income-$2.58M-$2.58MN/M vs Q1 2014 EPS Diluted-$0.06-$0.06N/M vs Q1 2014 Operating Income-$2,595,000N/M Operating Cash Flow-$1,147,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Filana Therapeutics, Inc. · CIK 1069530 · Engraved from SEC EDGAR
Free Cash Flowderived-$1,342,000N/M ended Mar 31, 2015 · filed May 8, 2015 · 38 d after period end